4BIO Capital leads $60 million in Series A funding from Oyster Therapeutics (formerly Kesama Therapeutics) to advance the next generation of protein-targeted therapies for Alzheimer's and other neurodegenerative diseases.
4BIO Capital leads $60 million in Series A funding from Oyster Therapeutics (formerly Kesama Therapeutics) to advance the next generation of protein-targeted therapies for Alzheimer's and other neurodegenerative diseases.
Want to see every report in real time?
Hundreds of sources worldwide, translated into your language, with alerts for what matters to you.
Sign up free Already have an account? Log in